Notable Price Action: Editas Medicine Inc Has Another Very Strong Trading Session

Notable Price Action: Editas Medicine Inc Has Another Very Strong Trading Session

The stock of Editas Medicine Inc (NASDAQ:EDIT) is a huge mover today! About 471,429 shares traded hands or 31.26% up from the average. Editas Medicine Inc (NASDAQ:EDIT) has declined 53.23% since March 2, 2016 and is downtrending. It has underperformed by 61.49% the S&P500.
The move comes after 5 months positive chart setup for the $653.19M company. It was reported on Oct, 5 by Barchart.com. We have $19.68 PT which if reached, will make NASDAQ:EDIT worth $143.70 million more.

Analysts await Editas Medicine Inc (NASDAQ:EDIT) to report earnings on November, 8. After $-0.54 actual earnings per share reported by Editas Medicine Inc for the previous quarter, Wall Street now forecasts 20.37% negative EPS growth.

According to Zacks Investment Research, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.”

More notable recent Editas Medicine Inc (NASDAQ:EDIT) news were published by: Finance.Yahoo.com which released: “Editas Medicine Expands Senior Management Team” on October 03, 2016, also Zacks.com with their article: “Editas Medicine (EDIT) Catches Eye: Stock Moves Up 11%” published on October 05, 2016, Quotes.Wsj.com published: “News Editas Medicine Inc.EDIT” on January 16, 2015. More interesting news about Editas Medicine Inc (NASDAQ:EDIT) were released by: Bostonglobe.com and their article: “Editas Medicine raises $94.4 million in year’s first IPO” published on February 02, 2016 as well as Marketwatch.com‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: February 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment